GlaxoSmithKline Pharmaceuticals (BOM:500660) Change In Receivables : ₹0 Mil (TTM As of Dec. 2024)

GlaxoSmithKline Pharmaceuticals Change In Receivables Chart

GlaxoSmithKline Pharmaceuticals Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
Change In Receivables		Get a 7-Day Free Trial					-0.50	-999.34	102.04	202.28	-302.69

GlaxoSmithKline Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

GlaxoSmithKline Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals  (BOM:500660) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

GlaxoSmithKline Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

2. In Ben Graham's calculation of liquidation value, GlaxoSmithKline Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

GlaxoSmithKline Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pharmaceuticals Business Description